The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.

Clare ArnottYuli HuangBrendon L NeuenGian Luca Di TannaChristopher P CannonRichard OhRobert EdwardsMary KavalamNorman RosenthalVlado PerkovicMeg J JardineKenneth MahaffeyBruce C Neal

Published in: Diabetes, obesity & metabolism (2020)

We identified no explanation for the difference in amputation risk between the CREDENCE trial and the CANVAS program. In the context of null effects of SGLT2 inhibition on amputation in CREDENCE and all other large trials, there is a possibility that the finding in CANVAS was the result of chance.

Keyphrases

lower limb
study protocol
phase iii
quality improvement
clinical trial
peripheral artery disease
phase ii
open label
breast cancer risk